Success Metrics

Clinical Success Rate
93.2%

Based on 41 completed trials

Completion Rate
93%(41/44)
Active Trials
2(4%)
Results Posted
37%(15 trials)
Terminated
3(5%)

Phase Distribution

Ph phase_1
7
12%
Ph not_applicable
13
23%
Ph phase_2
8
14%
Ph phase_3
6
11%
Ph phase_4
10
18%
Ph early_phase_1
5
9%

Phase Distribution

12

Early Stage

8

Mid Stage

16

Late Stage

Phase Distribution49 total trials
Early Phase 1First-in-human
5(10.2%)
Phase 1Safety & dosage
7(14.3%)
Phase 2Efficacy & side effects
8(16.3%)
Phase 3Large-scale testing
6(12.2%)
Phase 4Post-market surveillance
10(20.4%)
N/ANon-phased studies
13(26.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.7%

41 of 49 finished

Non-Completion Rate

16.3%

8 ended early

Currently Active

2

trials recruiting

Total Trials

57

all time

Status Distribution
Active(2)
Completed(41)
Terminated(8)
Other(6)

Detailed Status

Completed41
unknown6
Withdrawn5
Terminated3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
57
Active
2
Success Rate
93.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 15 (10.2%)
Phase 17 (14.3%)
Phase 28 (16.3%)
Phase 36 (12.2%)
Phase 410 (20.4%)
N/A13 (26.5%)

Trials by Status

unknown611%
completed4172%
recruiting24%
terminated35%
withdrawn59%

Recent Activity

Clinical Trials (57)

Showing 20 of 57 trialsScroll for more
NCT03794388Phase 3

Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery

Completed
NCT05840562Phase 3

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

Recruiting
NCT07237022

The Role of TRP Channels in DPN

Recruiting
NCT00004316Phase 1

Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis

Completed
NCT06809569Phase 1

A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)

Completed
NCT04283292Phase 4

Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome

Completed
NCT03321019

Airway Protective Mechanisms in PD (R01)

Completed
NCT03330639Not Applicable

Capsaicin in Treatment of Rhinogenic Headache

Withdrawn
NCT03722849Not Applicable

Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients

Completed
NCT05298202Phase 4

The Influence of Capsaicin Gel During Exercise Within the Heat

Completed
NCT05983263

Analgesic Efficacy of Capsaicin 8% Patch (QUTENZA®) in Coccygodygnia

Unknown
NCT05958173Not Applicable

Effects of 6-month of Treatment With TRPV1 and TRPA1 Agonists in Older Patients With OD

Unknown
NCT05543837Phase 2

Capsaicin for Cerebral Perfusion Augmentation

Completed
NCT02139852

Capsaicinoid Ingestion, Human Metabolism and Exercise

Withdrawn
NCT02138630Not Applicable

Capsaicinoid Ingestion, Human Metabolism and Exercise (Phase 2)

Withdrawn
NCT04918069Phase 2

Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN)

Completed
NCT01595620Early Phase 1

Cannabinoid Modulation of Pain

Completed
NCT04700007Not Applicable

Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project)

Completed
NCT05029297Phase 3

Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy.

Completed
NCT00771511Phase 4

Cervical Capsaicin for Labor Induction and Pain Relief

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
57